EUVIMEDEUVIMED entdecken
Klinische Studie

Single-Arm Investigator-Initiated Clinical Trial to Improve Germline Testing in At-Risk Patients With Prostate Cancer (IMPRINT)

Juan Javier-DesLoges, Ana Flores Pimentel iD, Samuel Pena, Yasoda Satpathy, Yu-Wei Chen iD, Michael James Randall, Tyler Stewart, Christopher J Kane, Aditya Bagrodia iD, Clara Hwang iD, Lin Lu iD, Matthew Savage iD und 2 weitere

JCO Oncology Practice · 2025

DOI: 10.1200/op-25-00266 ↗

Kurz gefasst

Klinische Studie in der Zeitschrift JCO Oncology Practice, 2025. Verfasst von Juan Javier-DesLoges und 13 weiteren Autor:innen. Beteiligte Einrichtung: University of California San Diego, Department of Urology, La Jolla, CA. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Genetic Testing, Patient Education as Topic, Germ-Line Mutation. Die Arbeit nennt 26 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Germline testing is recommended for patients with high-risk localized, locally advanced, and metastatic prostate cancer; however, implementation remains suboptimal. Novel strategies are needed to engage oncology clinicians and patients in germline testing. METHODS A single-arm investigator-initiated study, conducted from October 1, 2022, to December 31, 2023, used video education as pretest counseling for patients meeting National Cancer Comprehensive Network germline testing criteria. Patients attended a one-on-one in-person session with an educational video, followed by prevideo and postvideo questionnaires assessing knowledge and satisfaction. The primary end point was the proportion who underwent germline testing after intervention, compared with a contemporaneous standard-of-care (SOC) group. Secondary end points included changes in knowledge and perceptions. RESULTS All 50 enrolled patients completed the intervention. Patients were predominantly White (78.0%), non-Hispanic (92.0%), English-speaking (98.0%), and college-educated (70%). Most had high-risk localized (46.0%) or metastatic hormone-sensitive prostate cancer (26.0%). Germline testing uptake was significantly higher in the intervention group (82.0%, 41/50) compared with the SOC group (37.94%, 107/282, P < .001). In the intervention group, urologists ordered 22.5% of tests and medical oncologists ordered 77.5%. Pathogenic/likely pathogenic alterations were identified in 10.0% of patients. Most participants (64%) indicated that the most important factor in their decision was whether results could guide treatment. Those who declined testing cited lack of clinical value. Most scored high on the prevideo genetic knowledge test (mean 9.1/11.0) with no statistical difference postvideo ( P = .88). Most found the video satisfactory and useful (94%). CONCLUSION Germline testing uptake was high after video education. Most patients had high baseline genetic knowledge but were more likely to pursue testing after intervention if it influenced their treatment. Virtual educational aids should be integrated into clinical practice to increase testing rates.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsGenetic TestingPatient Education as TopicGerm-Line MutationHumansMaleMiddle AgedAgedSurveys and Questionnaires

Autor:innen und Institutionen

  • University of California San Diego, Department of Urology, La Jolla, CA.
  • University of California San Diego, Department of Medicine, Division of Hematology Oncology, La Jolla, CA.
  • Henry Ford Health, Department of Internal Medicine, Division of Hematology/Oncology, Detroit, MI.
  • University of California San Diego, The Herbert Wertheim School of Public Health and Human Longevity Science, Division of Biostatics and Bioinformatics, La Jolla, CA.
  • San Diego State University, School of Communications, San Diego, CA.

ORCID-Profile: Ana Flores Pimentel, Yu-Wei Chen, Aditya Bagrodia, Clara Hwang, Lin Lu, Matthew Savage, Rana R McKay

Zitieren

APA

Javier-DesLoges, J., Flores Pimentel, A., Pena, S., Satpathy, Y., Chen, Y. W., Randall, M. J., Stewart, T., Kane, C. J., Bagrodia, A., Hwang, C., Lu, L., Savage, M., Madlensky, L., & McKay, R. R. (2025). Single-Arm Investigator-Initiated Clinical Trial to Improve Germline Testing in At-Risk Patients With Prostate Cancer (IMPRINT). JCO Oncology Practice. https://doi.org/10.1200/op-25-00266

Vancouver

Javier-DesLoges J, Flores Pimentel A, Pena S, Satpathy Y, Chen YW, Randall MJ, et al. Single-Arm Investigator-Initiated Clinical Trial to Improve Germline Testing in At-Risk Patients With Prostate Cancer (IMPRINT). JCO Oncology Practice. 2025. doi:10.1200/op-25-00266

BibTeX
@article{JavierDesLoges2025,
  author = {Javier-DesLoges, Juan and Flores Pimentel, Ana and Pena, Samuel and Satpathy, Yasoda and Chen, Yu-Wei and Randall, Michael James and Stewart, Tyler and Kane, Christopher J and Bagrodia, Aditya and Hwang, Clara and Lu, Lin and Savage, Matthew and Madlensky, Lisa and McKay, Rana R},
  title = {Single-Arm Investigator-Initiated Clinical Trial to Improve Germline Testing in At-Risk Patients With Prostate Cancer (IMPRINT)},
  journal = {JCO Oncology Practice},
  year = {2025},
  doi = {10.1200/op-25-00266}
}
Kostenlos starten →